How Does Mounjaro Cause Weight Loss in the Body?

What are GIP and GLP-1, and why does targeting both matter?

Your body naturally produces two hormones after eating: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both are released from the gut in response to food and act as signals to the brain and pancreas that a meal has arrived. GLP-1 slows gastric emptying and promotes fullness; GIP appears to amplify these effects and may also influence how the body stores and burns fat. Together, they form a tightly integrated system that regulates hunger between meals.

Most weight-loss injections available in the UK (including Wegovy) activate only the GLP-1 pathway. Mounjaro's active ingredient, tirzepatide, activates both. This dual-agonist mechanism is what makes tirzepatide distinct, and it is cited by NICE in their appraisal of Mounjaro as the basis for its stronger average weight-loss results compared to earlier GLP-1 medicines. The NHS medicines page for tirzepatide describes this mechanism in plain terms for patients starting treatment.

The practical result is that appetite falls more consistently across the day, not just around meals. People taking Mounjaro often report that food simply feels less urgent, that they stop eating sooner and feel satisfied with smaller portions without having to consciously restrain themselves.

Does Mounjaro directly affect the brain as well as the gut?

Yes. Both GIP and GLP-1 receptors are found not only in the digestive system but in areas of the brain involved in appetite regulation, including the hypothalamus. When tirzepatide activates these receptors centrally, it reduces what researchers call the "hedonic" drive to eat, the pull towards food that exists separately from true hunger. This is why many people on Mounjaro find their relationship with food shifts: cravings become quieter and it becomes easier to stop at the point of satisfaction rather than continuing past it.

This central action also helps explain why weight loss on Mounjaro is meaningfully greater than simply eating a bit less. The medicine changes the signalling environment the brain is working within. For a fuller account of how these mechanisms translate into results, the Mounjaro weight-loss results page covers the SURMOUNT trial data in detail.

It is also worth noting the connection between these hormones and insulin sensitivity. Tirzepatide improves how the body responds to insulin, which has downstream effects on fat storage, particularly visceral fat around the organs. If you are interested in how this plays out metabolically, the page on Mounjaro and insulin resistance goes into this further.

Does Mounjaro cause weight loss through reduced calories alone, or something else?

Primarily through calorie reduction, but the mechanism driving that reduction is biological, not a matter of willpower. Because gastric emptying slows, a meal that previously left someone feeling satisfied for two hours might now keep them comfortable for four. Because appetite signals are quieter, many people naturally eat less at each sitting. The calorie deficit that results is real; what changes is how the body creates it.

There is also evidence from research programmes that tirzepatide may have some independent metabolic effects beyond appetite suppression (including on how fat tissue is regulated) though the dominant mechanism in practice is the reduction in energy intake. NICE's appraisal (TA1026), which recommended tirzepatide for eligible adults in England, notes results from clinical trials involving thousands of participants and acknowledges indirect comparisons that favour tirzepatide over semaglutide 2.4mg; the recommendations chapter of NICE TA1026 sets out who qualifies and what the evidence base supports.

It is also the reason that stopping Mounjaro without addressing diet and activity tends to lead to weight regain, the medicine modulates the biological environment; it does not permanently reset it. Most prescribers discuss long-term plans at the outset. If you are thinking about cost over time, a plain breakdown of what private treatment involves is on the Mounjaro UK pricing context page.

What side effects come from the same mechanisms that cause weight loss?

Most of the common side effects of Mounjaro arise directly from the same biology that produces weight loss. Slowing gastric emptying is helpful for appetite and fullness, but it can also cause nausea, especially in the early weeks of treatment or after a dose increase. The gut's response to the change in hormone signalling can include loose stools or constipation, indigestion, reflux, and occasional vomiting. Fatigue, headache and dizziness are reported by some people, particularly early on.

These effects are typically most noticeable in the first one to two weeks at a new dose and ease as the body adjusts. Starting at 2.5mg (which is a tolerability dose, designed to settle the system before the dose is increased) is the standard approach and is set out in the medicine's prescribing information. Some people find it helpful to keep their pen in the fridge door and pair their weekly injection with a fixed routine, so it becomes easy to remember without feeling clinical.

Rare but serious effects include pancreatitis. The MHRA issued guidance in January 2026 emphasising that severe stomach pain reaching the back is a reason to seek urgent medical attention. Our overview of how Mounjaro works includes a fuller side-effect section, and you can report anything unexpected directly through the MHRA's Yellow Card scheme. There is also a separate resource if you have seen reports about Mounjaro and sight changes, which addresses that question specifically.

If you have read this far and want to explore whether treatment might be suitable for you, checking your eligibility through a free consultation with a GPhC-registered prescriber is the natural next step.